Biogen (BIIB) Share-based Compensation (2009 - 2026)
Biogen (BIIB) posted quarterly Share-based Compensation of $77.4 million for Q2 2026, up 3.34% year-over-year from $74.9 million in Q2 2025, and down 7.86% quarter-over-quarter from $84.0 million in Q1 2026.
Biogen (BIIB) Share-based Compensation (2009 - 2026) Analysis & Trends
Biogen's Share-based Compensation history runs 18 years deep, the most recent figure standing at $77.4 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 3.34% year-over-year to $77.4 million; the TTM figure through Jun 2026 stood at $296.3 million (down 2.44% YoY), while the FY2025 annual figure was $290.8 million, changed 0.14% from the prior year.
- Share-based Compensation for Q2 2026 stood at $77.4 million, down from $84.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $84.0 million in Q1 2026, with the low at $54.9 million in Q4 2023.
- The 5-year median for Share-based Compensation is $72.1 million (2023), against an average of $70.1 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 36.79% in 2024, then declined 20.64% in 2025.
- Biogen's Share-based Compensation stood at $67.2 million in 2022, then retreated by 18.3% to $54.9 million in 2023, then jumped by 36.79% to $75.1 million in 2024, then dropped by 20.64% to $59.6 million in 2025, then advanced by 29.87% to $77.4 million in 2026.
- Business Quant data shows BIIB's Share-based Compensation at $77.4 million in Q2 2026, $84.0 million in Q1 2026, and $59.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.81 Bn | 632.06 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 470.36 Bn | 463.79 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 375.71 Bn | 368.57 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.50 Bn | 295.81 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.38 Bn | 252.48 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.44 Bn | 222.45 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 181.93 Bn | 178.75 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.38 Bn | 147.68 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.17 Bn | 102.00 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.03 Bn | 30.74 Bn | 1.96 Bn | 77.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.40 Mn |
| Jun 30, 2026 | 77.40 Mn |
| Mar 31, 2026 | 84.00 Mn |
| Mar 31, 2026 | 84.00 Mn |
| Dec 31, 2025 | 59.60 Mn |
| Dec 31, 2025 | 59.60 Mn |
| Sep 30, 2025 | 75.30 Mn |
| Sep 30, 2025 | 75.30 Mn |
| Jun 30, 2025 | 74.90 Mn |
| Jun 30, 2025 | 74.90 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Dec 31, 2024 | 75.10 Mn |
| Dec 31, 2024 | 75.10 Mn |
| Sep 30, 2024 | 72.70 Mn |
| Sep 30, 2024 | 72.70 Mn |
| Jun 30, 2024 | 70.60 Mn |
| Jun 30, 2024 | 70.60 Mn |
| Mar 31, 2024 | 72.80 Mn |
| Mar 31, 2024 | 72.80 Mn |